Payment overview · 2025
General Payments
$890.96
46 reported records · 12 companies
Healthcare provider profile · identity verified
Douglas Eugene Vogt, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBIA, MO · NPI 1669430070
Verified facts
What the public records show
CMS Open Payments records show Douglas Eugene Vogt, M.D. received $890.96 in general payments during 2025 across 46 reported records.
ABBVIE INC. accounted for 31.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $282.26 | 31.7% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $206.19 | 23.1% | 11 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $110.97 | 12.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.66 | 9.6% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $45.07 | 5.1% | 2 | 2025 |
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $33.51 | 3.8% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $29.74 | 3.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.25 | 3.2% | 1 | 2025 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.00 | 2.2% | 1 | 2025 |
| Almirall LLC | Unresolved — no canonical attribution shown | $17.87 | 2.0% | 1 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $16.09 | 1.8% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $15.35 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $890.96 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $193.56 | 13 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Lilly USA, LLC | $177.98 | 9 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $177.98 | 9 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $140.71 | 5 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $88.70 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $85.66 | 4 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $45.07 | 2 | 2025 |
Source payment records
|
|||||
| ADBRY Normalized: adbry |
Biological | LEO Pharma Inc. | $33.51 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.21 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.21 | 2 | 2025 |
Source payment records
|
|||||
| JUBLIA Normalized: jublia |
Drug | Ortho Dermatologics, a division of Bausch Health US, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Klisyri Normalized: klisyri |
Drug | Almirall LLC | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| Winlevi Normalized: winlevi |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 97 |
| Omeprazole | Omeprazole | 300 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 281 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 67 |
| Losartan Potassium | Losartan Potassium | 260 | 53 |
| Tramadol Hcl | Tramadol Hcl | 211 | 35 |
| Metformin Hcl | Metformin Hcl | 201 | 54 |
| Gabapentin | Gabapentin | 194 | 48 |
| Lisinopril | Lisinopril | 179 | 47 |
| Sertraline Hcl | Sertraline Hcl | 166 | 26 |
| Montelukast Sodium | Montelukast Sodium | 151 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 141 | 32 |
| Furosemide | Furosemide | 136 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 35 |
| Carvedilol | Carvedilol | 123 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 33 |
| Alprazolam | Alprazolam | 120 | 23 |
| Meloxicam | Meloxicam | 116 | 28 |
| Potassium Chloride | Potassium Chloride | 112 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 28 |
| Trazodone Hcl | Trazodone Hcl | 101 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 98 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 20 |
| Allopurinol | Allopurinol | 90 | 23 |
| Prednisone | Prednisone | 89 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 24 |
| Eliquis | Apixaban | 80 | 15 |
| Simvastatin | Simvastatin | 76 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 76 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 13 |
| Donepezil Hcl | Donepezil Hcl | 73 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 17 |
| Cephalexin | Cephalexin | 64 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 13 |
| Spironolactone | Spironolactone | 64 | 13 |
| Lorazepam | Lorazepam | 63 | 13 |
| Synthroid | Levothyroxine Sodium | 63 | 14 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 12 |
| Lovastatin | Lovastatin | 59 | 15 |
| Famotidine | Famotidine | 58 | 11 |
| Finasteride | Finasteride | 55 | 13 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 55 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 40 |
| Azithromycin | Azithromycin | 50 | 29 |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 12 |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Celecoxib | Celecoxib | 42 | 11 |
| Topiramate | Topiramate | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 12 |
| Diazepam | Diazepam | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Atenolol | Atenolol | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $890.96 · 46 records | ABBVIE INC. | ACTHAR, ADBRY, DUPIXENT, EBGLYSS, JUBLIA, Klisyri, LEQVIO, MOUNJARO, OTEZLA, RINVOQ, SKYRIZI, SMARTVEST, TALTZ, Winlevi, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error